Zevra Therapeutics Inc
NASDAQ:ZVRA
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
4.26
9.585
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one ZVRA stock under the Base Case scenario is 14.25 USD. Compared to the current market price of 9.43 USD, Zevra Therapeutics Inc is Undervalued by 34%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Zevra Therapeutics Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for ZVRA cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Zevra Therapeutics Inc
Balance Sheet Decomposition
Zevra Therapeutics Inc
Current Assets | 99.4m |
Cash & Short-Term Investments | 89.4m |
Receivables | 7.8m |
Other Current Assets | 2.3m |
Non-Current Assets | 92.1m |
Long-Term Investments | 6.1m |
PP&E | 1.4m |
Intangibles | 75.3m |
Other Non-Current Assets | 9.3m |
Current Liabilities | 34.5m |
Accounts Payable | 24.5m |
Accrued Liabilities | 540k |
Other Current Liabilities | 9.5m |
Non-Current Liabilities | 87.3m |
Long-Term Debt | 58.9m |
Other Non-Current Liabilities | 28.4m |
Earnings Waterfall
Zevra Therapeutics Inc
Revenue
|
24.8m
USD
|
Cost of Revenue
|
-11.5m
USD
|
Gross Profit
|
13.3m
USD
|
Operating Expenses
|
-99.6m
USD
|
Operating Income
|
-86.3m
USD
|
Other Expenses
|
1.3m
USD
|
Net Income
|
-84.9m
USD
|
Free Cash Flow Analysis
Zevra Therapeutics Inc
USD | |
Free Cash Flow | USD |
ZVRA Profitability Score
Profitability Due Diligence
Zevra Therapeutics Inc's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
Score
Zevra Therapeutics Inc's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
ZVRA Solvency Score
Solvency Due Diligence
Zevra Therapeutics Inc's solvency score is 37/100. The higher the solvency score, the more solvent the company is.
Score
Zevra Therapeutics Inc's solvency score is 37/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ZVRA Price Targets Summary
Zevra Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for ZVRA is 21.42 USD with a low forecast of 17.17 USD and a high forecast of 26.25 USD.
Dividends
Current shareholder yield for ZVRA is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
ZVRA Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Zevra Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. The company is headquartered in Celebration, Florida and currently employs 36 full-time employees. The company went IPO on 2015-04-16. The firm is engaged in creating therapies for diseases with limited or no treatment options. The firm has a diverse portfolio of products and product candidates, which includes a combination of both a clinical-stage pipeline and commercial stage assets. The company employs its LAT platform technology to create a portfolio of approved products. Its product candidates include Arimoclomol, KP1077IH, KP1077N and AZSTARYS. Arimoclomol is an orally delivered, investigational product candidate being developed for Niemann-Pick disease type C (NPC). KP1077 is the Company's lead clinical development product candidate, which is being developed as a treatment for idiopathic hypersomnia (IH) and narcolepsy. KP1077 is comprised solely of serdexmethylphenidate (SDX), the Company's prodrug of d-methylphenidate (d-MPH). AZSTARYS is a prodrug for the treatment of ADHD in patients aged six years or older.
Contact
IPO
Employees
Officers
The intrinsic value of one ZVRA stock under the Base Case scenario is 14.25 USD.
Compared to the current market price of 9.43 USD, Zevra Therapeutics Inc is Undervalued by 34%.